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Background: To compare the safety and efficacy of loteprednol etabonate ophthalmic o  intment 
0.5% (LE ointment), a new topical ointment formulation, with vehicle for the treatment of 
inflammation and pain following cataract surgery.
Methods: Two randomized, multicenter, double-masked, parallel-group, vehicle-controlled stud-
ies were conducted. Patients aged $18 years with a combined postoperative a  nterior c  hamber 
cells and flare (ACI) $ Grade 3 following u  ncomplicated cataract surgery participated in seven 
study visits. Patients self-administered either topical LE ointment or vehicle four times daily for 
14 days. Efficacy outcomes included the proportion of patients with complete resolution of ACI 
and the proportion of patients with no (Grade 0) pain at postoperative day 8. Safety outcomes 
included the incidence of adverse events, ocular symptoms, changes in intraocular pressure and 
visual acuity, and biomicroscopy and   funduscopy findings.
Results: Data from the two studies were combined. The integrated intent-to-treat population 
consisted of 805 patients (mean [standard deviation] age 69.0 [9.2] years; 58.0% female and 
89.7% white). Significantly more LE ointment-treated patients than vehicle-treated patients had 
complete resolution of ACI (27.7% versus 12.5%) and no pain (75.5% versus 43.1%) at day 8 
(P , 0.0001 for both). Fewer LE ointment-treated patients required rescue   medication (27.7% 
versus 63.8%), and fewer had an ocular adverse event (47.2% versus 78.0%, P , 0.0001) while 
on study treatment. The most common ocular adverse events with LE   ointment were anterior 
chamber inflammation,   photophobia, corneal edema, conjunctival hyperemia, eye pain, and 
iritis. Mean   intraocular pressure decreased in both treatment groups. Four patients had increased 
intraocular   pressure $10 mmHg (three LE ointment and one vehicle) prior to rescue   medication. 
Visual acuity and dilated funduscopy results were similar between the treatment groups, with 
the exception of visual acuity at visits 5 and 6, which favored LE ointment.
Conclusion: LE ointment was efficacious and well tolerated in the treatment of ocular 
in  flammation and pain following cataract surgery.
Keywords: loteprednol etabonate, ophthalmic ointment, postoperative inflammation, 
p  ostoperative pain, cataract surgery, intraocular pressure
Introduction
Topical corticosteroids are useful in a variety of ophthalmic conditions and are 
  generally indicated for treatment of steroid-responsive inflammatory conditions 
of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.1 
Although c  orticosteroids are widely used as topical agents for ocular inflammation, 
most possess a risk profile that limits their general utility. A common risk associated 
with corticosteroid therapy is elevation of intraocular pressure (IOP).2,3 A rise in IOP 
may result in optic nerve damage and visual field defects. In addition, chronic use of Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
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corticosteroids may result in the development of cataracts.4 
Therefore, it is recommended that patients limit their expo-
sure to corticosteroids and have their IOP routinely monitored 
during treatment.
Loteprednol etabonate (LE) is an ester   corticosteroid 
specifically designed to be metabolically labile, s  ubject to 
predictable hydrolysis, resulting in the formation of i  nactive 
metabolites.5,6 Specifically, the labile 17-β-chloromethyl ester 
function undergoes de-esterification to an inactive carboxylic 
acid metabolite after exerting its effect or when unbound due 
to receptor saturation, thereby minimizing the likelihood 
of toxicity.7 Hence, LE has a lower   propensity to induce 
e  levation in IOP even when used in known steroid   responders.8 
The absence of the ketone group at   position C-20 should also 
reduce the likelihood of   molecular i  nteraction with amino 
acid residues on the o  cular lens proteins and formation of 
steroid-protein adducts, a process which may be involved in 
cataract formation. The b  iochemical mechanism of corticos-
teroid cataractogenesis has been shown to involve reaction of 
the C-20 steroid ketol moiety with lens protein amino groups 
to form a Schiff base intermediate, followed by interaction 
with the C-21 hydroxyl to produce a stable ketoamine via 
a Heyns rearrangement.9 The metabolism of LE to inactive 
metabolites and the absence of the ketone group at position 
C-20 should offer a therapeutic advantage over conventional 
steroids by reducing the risk for steroid-induced cataracts 
and elevation of IOP.
LE has been approved by the US Food and Drug 
A  dministration and other global health authorities for several 
clinical indications. In the US, LE ophthalmic suspension 0.5% 
(Lotemax®, Bausch and Lomb Inc, Rochester, NY) is indicated 
for the treatment of steroid-responsive inflammatory conditions 
of the palpebral and bulbar conjunctiva, cornea, and anterior 
segment of the globe, and postoperative inflammation following 
ocular surgery.10 In clinical studies, LE ophthalmic suspension 
0.5% was shown to be effective in the treatment of inflamma-
tion associated with giant papillary conjunctivitis,11,12 seasonal 
allergic conjunctivitis,13 dry eye,14 anterior uveitis,15 and cataract 
surgery.16,17 In addition, LE ophthalmic suspension 0.5% has 
been shown to have a decreased incidence of significant IOP 
increase (ie, $10 mmHg) compared with dexamethasone,18 as 
well as a smaller mean change from baseline IOP compared 
with both dexamethasone18,19 and prednisolone acetate.7
The availability of an ointment formulation in the already 
well characterized 0.5% LE concentration would allow 
physicians a choice of dosage forms when treating ocular 
inflammation. The primary objective of the two Phase III 
clinical studies described herein was to compare the safety 
and efficacy of LE ophthalmic ointment 0.5% with that of the 
vehicle for the treatment of inflammation and pain following 
cataract surgery. The inflammation and pain associated with 
cataract surgery is a good model for evaluating treatment 
of intraocular inflammation. The two studies had identical 
designs, including study endpoints, choice of control group, 
study duration, statistical methods, patient population, and 
dosage. The efficacy and safety data were collected in an iden-
tical manner in both studies. Therefore, integrated analyses of 
the pooled data from the two studies were performed.
Methods
Two randomized, multicenter, double-masked, parallel-group, 
vehicle-controlled studies were conducted at 33 centers in the 
US between 2008 and 2009 (ClinicalTrials.gov. Identifiers: 
NCT00645671 and NCT00699153). The studies were conducted 
in accordance with the Declaration of Helsinki (2004) and were 
approved by the institutional review board of each center or by 
Schulman Associates Institutional Review Board Inc (  Cincinnati, 
OH). All patients (or a legally authorized representative) gave 
written informed consent prior to study enrollment.
Patients
Eligible patients were at least 18 years of age, were candidates 
for routine, uncomplicated cataract surgery (phacoemulsifi-
cation with posterior chamber intraocular implantation, not 
combined with any other surgery), had potential postop-
erative pin-hole Snellen visual acuity of at least 20/200 in 
the study eye, were not of childbearing potential, or had a 
negative urine pregnancy test at screening. Furthermore, to 
be eligible for randomization, patients who had undergone 
routine, u  ncomplicated cataract surgery were required to 
have a combined grade of $3 for anterior chamber cells 
and anterior chamber flare (anterior chamber inflammation 
[ACI]) at visit 3 (postoperative day 1). Patients were excluded 
if they were expected to require concurrent ocular therapy 
(either eye) with nonsteroidal anti-inflammatory drugs, mast 
cell stabilizers, antihistamines, or decongestants, as well as 
i  mmunosuppressants, and s  ystemic or ocular   corticosteroids 
during the 18 days following surgery. Limitations of use 
for each of these therapies were also prespecified prior 
to cataract surgery. Subjects with known hypersensitivity 
or contraindication to the study drug or their components 
were also excluded.
study procedures
The study period for each patient was approximately 
four weeks in duration and required seven clinic visits. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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  Eligibility of patients for each study was determined at 
the screening visit (visit 1) by a clinical assessment of 
ocular signs and   symptoms in both eyes. The screening eye 
examinations included pinhole visual acuity, biomicroscopy, 
funduscopy, and IOP measurement. Cataract surgery was 
performed at visit 2, within 14 days of the screening visit. 
At visit 3, on postoperative day 1 (18–34 hours after surgery), 
the eye examinations performed at visit 1 were repeated, with 
the exception of funduscopy. Anterior   chamber cells and 
flare were assessed and a combined ACI grade   determined. 
Patients with ACI $ 3 were considered eligible for the study 
and were randomized to treatment. Patients with ACI , 3 
were   considered screen failures. All eligible patients were 
randomized to receive either study drug (LE ointment or 
vehicle) in a 1:1 ratio stratified by site. Patient supplies were 
labeled according to a computer-generated randomization 
schedule and dispensed sequentially by kit number within a 
site. Patients self-administered a 0.5 inch (1.3 cm)   ribbon of 
study drug (LE ointment or vehicle) to the lower cul de sac 
of the study eye four times daily, at approximately four-hour 
intervals for 14 days, and recorded the times of instillation 
in a study diary. The initial dose of study drug occurred in 
the clinic at visit 3. The last   treatment a  dministration was the 
fourth dose on the day before visit 6. The eye e  xaminations 
performed at visits 1 and 3 were repeated at visit 4 
(  postoperative day 3), visit 5 (  postoperative day 8), visit 6 
(postoperative day 15), and visit 7 (  postoperative day 18), 
with the exception of funduscopy. Funduscopy was   performed 
at visits 1 and 6 only.
During the study, any subjects not responding adequately 
to study treatment could be placed on rescue therapy. The 
  initiation of rescue therapy and the type of medication 
given to a subject as rescue therapy was at the i  nvestigator’s 
  discretion. If the investigator determined that rescue therapy 
was needed, the use of study medication was stopped and 
an adverse event of worsening inflammation or persis-
tent i  nflammation was recorded. The subjects continued 
  participation in the study and were followed through visit 7, 
  completing all study assessments despite having discontinued 
use of the study medication.
Efficacy and safety outcomes
The primary efficacy endpoints for each study were the 
proportion of patients with complete resolution of ACI at 
visit 5, and the proportion of patients with no (Grade 0 ) pain 
at visit 5. Secondary efficacy endpoints included assessments 
at each visit of the proportion of patients with complete 
resolution of ACI, complete resolution of anterior chamber 
cells and anterior chamber flare individually, the proportion 
of patients with no (Grade 0) pain, and the change from 
baseline in ACI. Anterior chamber cells were rated as 0 = no 
cells seen, 1 = 1–5 cells, 2 = 6–15 cells, 3 = 16–30 cells, or 
4 = 30 cells. Anterior chamber flare was rated as 0 = none, 
1 = mild, 2 = moderate, 3 = severe, or 4 = very severe. 
ACI represented a combination of the grade for cells and 
flare. Pain was measured on a scale of 0–5, from 0 = no pain 
to 5 = severe pain.
Safety endpoints included the incidence of adverse events, 
change from baseline in IOP and visual acuity, and the 
absence/presence of abnormal slit lamp findings and a variety 
of subjective symptoms (discharge, dryness, itching, pain, 
photophobia, and tearing). Ocular symptoms were c  onsidered 
as both safety and tolerability measures. All adverse events 
were documented, assessed for relationship to study drug, 
and rated for intensity (mild, moderate, or severe). Slit lamp 
fi  ndings were graded using standard clinical scales. For ocular 
symptoms, ocular pain was graded as previously described, 
while photophobia, itching, tearing, dryness, and discharge, 
were rated on a scale of 0–3, from 0 = absent to 3 = severe. 
IOP was measured using Goldmann a  pplanation tonometry 
(or an equivalent technique), following the assessment of 
ocular signs and symptoms. Dilated fundus examinations 
were performed at visits 1 and 6 to assess the retina, macula, 
choroid, and optic nerve for abnormalities.
statistical analyses
Approximately 400 patients were planned to be enrolled 
in each study (200 patients per treatment group), to yield 
approximately 180 patients per treatment group completing 
the study based on a sample size of 180 patients per treatment 
group providing 99% power to detect a difference between 
the LE ointment and vehicle treatment groups in the propor-
tion of patients with complete resolution of ACI as well as 
in the proportion of patients with no (Grade 0) pain at visit 
5 (postoperative day 8). With more than 300 patients/eyes 
in the integrated safety analysis, there was at least a 95% 
chance of observing adverse events with an incidence of 
1% or greater.
Results from the two studies were combined for integrated 
analyses of all endpoints. Efficacy endpoints were evaluated in 
all randomized patients (the intent-to-treat [ITT] population). 
The analyses of the primary efficacy endpoints tested the 
difference in the proportion of patients with complete 
resolution of ACI and the difference in the p  roportion of 
patients with no (Grade 0) pain between treatments at visit 5 
using the Pearson χ2 test and Cochran-Mantel-Haenszel test Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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stratified by center at the α = 0.05 level.20 Missing data and 
data from patients placed on rescue medication prior to visit 
5 were imputed as failures. For analysis of the secondary 
efficacy endpoints, the differences in the proportion of 
patients with complete resolution of ACI and the proportion 
of patients with no (Grade 0) pain were independently tested 
at each visit using the Pearson χ2 test. Additionally, anterior 
chamber cells and anterior chamber flare were analyzed sepa-
rately at each visit, as was the change from baseline in ACI. 
Again, differences between treatments were tested using the 
Pearson χ2 test and Cochran-Mantel-Haenszel test stratified 
by center, and patients placed on r  escue medication were 
imputed as failures. For consistency of presentation, results 
for the Pearson χ2 analysis are reported, and any differences 
in statistical test results are noted.
The safety analysis included all patients who received 
at least one dose of study drug. The proportions of patients 
reporting adverse events, mean changes in IOP, and propor-
tion of patients with change in IOP $ 10 mmHg, visual 
acuity, biomicroscopy, and funduscopy findings were tabu-
lated for each treatment group at each visit. To avoid the 
confounding effect of concomitant rescue   medication, safety 
data collected prior to rescue medication were   analyzed. 
Between-group comparisons of the proportions of patients 
experiencing adverse events were evaluated using the Fisher’s 
exact test.20
Ocular symptoms were compared between treatment 
groups both as absence versus presence of a symptom 
(Pearson χ2 test) and as change from baseline severity 
(Wilcoxon rank sum test). For these analyses, patients who 
used rescue medication prior to the visit being summarized 
were excluded.
All analyses were conducted using the Statistical Analysis 
System, version 9.1 (SAS Institute Inc, Cary, NC).
Results
study population
Patients were recruited from 33 US sites. A total of 
805 patients were randomized to treatment (404 patients 
to LE ointment and 401 patients to vehicle) and were 
included in the ITT population (Figure 1); all 805 patients 
received at least one dose of study drug and were included 
in the safety population. Six patients randomized to vehicle 
received LE ointment and five patients randomized to LE 
ointment received vehicle, resulting in a safety population 
of 405 and 400 patients in the LE ointment and vehicle treat-
ment groups, respectively. Almost all randomized patients 
c  ompleted the study, ie, 400 (99.0%) patients randomized to 
LE ointment and 393 (98.0%) patients randomized to vehicle. 
Twelve patients (1.5%) were discontinued from the study, 
including four LE ointment and eight vehicle. Reasons for 
discontinuation included patient withdrawal (four vehicle), 
adverse events (three vehicle), failure to follow study proce-
dures (two LE ointment), investigator decision (one vehicle), 
loss to follow-up (one LE ointment), and “other reasons” 
(one LE ointment).
Patient demographic characteristics for the ITT popu-
lation are shown in Table 1. Demographics were similar 
for the LE ointment and vehicle treatment groups. The 
  majority of patients were white (89.7%) and female 
(58.0%). The mean (standard deviation [SD]) age was 69.0 
(9.16) years, with an overall age range of 21 to 94 years. 
Ocular and nonocular medical histories were generally 
similar between treatments, and indicative of a study popu-
lation nearing the seventh decade of life. Based on patient 
diaries, more than 90% of patients in the LE ointment and 
Randomized 
(n = 805)
LE ointment
 (intent-to-treat population)
(n = 404)
Vehicle
(intent-to-treat population)
(n = 401)
Withdrawn (n = 4) 
Study procedures (2)
Lost to follow-up (1)
Other (1)
Withdrawn (n = 8)
Patient withdrawal (4)
AEs (3)
Investigator decision (1)
Completed
(n = 400)
Completed
(n = 393)
Figure 1 Flow of patients through the study.
Abbreviations: Ae, adverse event; Le, loteprednol etabonate.
Table 1 Demographics, intent-to-treat population
LE ointment  
(n = 404)
Vehicle  
(n = 401)
Overall  
(n = 805)
Age (years)
  Mean (sD) 68.7 (9.26) 69.2 (9.06) 69.0 (9.16)
  Minimum, maximum 21, 92 38, 94 21, 94
 , 65 116 (28.7%) 105 (26.2%) 221 (27.5%)
 $ 65 177 (43.8%) 185 (46.1%) 362 (45.0%)
 $ 75 111 (27.5%) 111 (27.7%) 222 (27.6%)
gender
  Male 171 (42.3%) 167 (41.6%) 338 (42.0%)
  Female 233 (57.7%) 234 (58.4%) 467 (58.0%)
race
  White 365 (90.3%) 357 (89.0%) 722 (89.7%)
  nonwhite 39 (9.7%) 44 (11.0%) 83 (10.3%)
Abbreviations: Le, loteprednol etabonate; sD, standard deviation.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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vehicle t  reatment groups were at least 80% compliant with 
t  reatment administration.
A total of 112 (27.7%) patients randomized to LE 
ointment and 256 (63.8%) patients randomized to vehicle 
required rescue therapy (nonsteroidal anti-inflammatory 
drugs and/or corticosteroids) during the study. An   additional 
18 and four patients in the LE ointment and vehicle t  reatment 
groups, respectively, received rescue therapy at study exit. 
Figure 2 shows the proportion of subjects who required 
rescue medication use prior to each visit. Prior to visit 5, 
rescue therapy was initiated for 35 (8.7%) patients in the LE 
o  intment group versus 129 (32.2%) patients in the vehicle 
group. The use of rescue medication decreased o  verall 
exposure to assigned treatments, especially in the vehicle 
group. Mean (SD) treatment exposure was 12.9 (3.43) days 
for patients randomized to LE ointment, with a median expo-
sure of 14 days, and 9.0 (5.12) days for patients randomized 
to vehicle, with a median exposure of 8.0 days.
Efficacy outcomes
Significantly more patients randomized to LE ointment had 
complete resolution of ACI, and no (Grade 0) pain at visit 
5 (Table 2) compared with patients randomized to vehicle. 
Complete resolution of ACI was observed for 112 (27.7%) 
patients in the LE ointment group compared with 50 (12.5%) 
patients in the vehicle group (P , 0.0001). Additionally, 305 
(75.5%) LE ointment patients compared with 173 (43.1%) 
vehicle patients had no (Grade 0) pain (P , 0.0001). When the 
primary analyses were repeated using the per protocol popu-
lation, the results were similar to that of the ITT population, 
(P , 0.0001 for ACI and for pain). Furthermore, subgroup 
analysis for patients stratified by age (,65 years, 65–75 years, 
and .75 years) returned similar results (P # 0.0245 
for ACI and P # 0.0001 for pain). As i  ndicated above, 
six patients randomized to vehicle received LE   ointment and 
five patients randomized to LE ointment received vehicle. 
  Outcomes for the primary analysis were also similar when 
the ITT p  opulation was analyzed as treated, with complete 
resolution of ACI observed for 115 (28.4%) versus 47 (11.8%) 
of LE ointment and vehicle-treated patients, respectively, and 
no (Grade 0) pain observed in 308 (76.0%) versus 170 (42.5%) 
of LE   ointment and v  ehicle-treated patients, respectively 
(P , 0.0001 for both).
Results of the secondary outcome measures were in 
  agreement with the primary outcome measures. Significantly 
more patients randomized to LE ointment compared with 
patients randomized to vehicle had complete r  esolution 
of ACI and anterior chamber cells at visits 5–7; and ante-
rior chamber flare as well as no (Grade 0) pain at visits 
4–7 (  Figure 3). Baseline mean (SD) ACI severity was 
3.7 (0.75) and 3.7 (0.82) in the LE ointment and vehicle 
treatment groups, respectively. Mean change from base-
line ACI showed an improvement in both groups, with a 
mean (SD) change of -1.1 (1.14), -2.2 (1.41), -2.6 (1.48), 
and -2.6 (1.52) for the LE ointment group and a mean change 
of -0.5 (1.45), -0.7 (1.81), -1.0 (1.95), and -1.1 (1.98) for 
the vehicle group at visits 4–7, respectively. Mean changes 
were consistently and significantly lower in the LE ointment 
treatment group at each of these visits (P , 0.0001).
Tolerability of the study medications was judged from 
assessment of ocular symptoms at baseline and at each visit. 
At baseline (visit 3), under 5% of subjects had symptoms 
of ocular discharge, dryness, or itching. The proportion of 
subjects with these symptoms and their change from baseline 
at visits 4–7 were similar between treatment groups, with 
the exception of ocular discharge at post-treatment visit 7, 
which favored vehicle (4.8% versus 0.7%, P = 0.0306), and 
dryness at visit 5, which favored LE ointment (13.7% versus 
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Figure 2 Proportion of patients with rescue medication use prior to each visit.
Abbreviation: Le, loteprednol etabonate.
Table 2 Resolution of anterior chamber cells and flare and pain 
at visit 5: integrated intent-to-treat population
LE ointment 
(n = 404)
Vehicle 
(n = 401)
Difference  
(95% CI)b 
P valuec
Complete resolution  
  of anterior chamber 
  cells and flarea
112 (27.7%) 50 (12.5%) 15.3% 
(9.6%, 20.9%) 
,0.0001
grade 0 (no) paina 305 (75.5%) 173 (43.1%) 32.4%  
(25.7%, 39.0%)   
,0.0001
Notes: aPatients who had missing data or took rescue medication prior to visit 5 
were imputed as failures; bDifference in percentages; 95% Ci based on asymptotic 
normal approximations; cP values from Pearson χ2 test.
Abbreviations: LE, loteprednol etabonate; CI, confidence interval.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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20.6%, P = 0.0213). Of the subjects who had discharge at 
visit 7, all had mild discharge, and all but one either had 
discharge that was resolved previously and reported again 
or had discharge reported for the first time at visit 7. The 
proportions of patients in the LE ointment group and vehicle 
group with ocular pain, photophobia, and tearing at baseline 
were 44.1% versus 46.6%, 57.9% versus 55.9%, and 37.1% 
versus 35.7%, respectively. There were fewer subjects in the 
LE ointment group compared with the vehicle group having 
pain at visit 4 (24.9% versus 54.5%) and visit 5 (16.4% 
versus 35.2%), and ocular pain either improved or did not 
change from baseline for 92.0% versus 66.2% of subjects, 
respectively, at visit 4 and for 91.0% versus 78.7% of sub-
jects, respectively, at visit 5 (P , 0.0001 for all). Likewise, 
there were fewer subjects in the LE ointment group compared 
with the vehicle group with photophobia at visit 4 (45.6% 
versus 64.9%) and visit 5 (40.0% versus 58.8%) and tearing 
at visit 4 (22.9% versus 34.6%) and visit 5 (16.4% versus 
25.1%, P , 0.01 for all). Photophobia either improved or 
did not change from baseline for 88.5% versus 70.7% of 
subjects at visit 4 and for 86.3% versus 71.2% of subjects 
at visit 5 (P , 0.0001 for both), while tearing improved 
or did not change from baseline in 91.8% versus 82.8% of 
subjects at visit 4 (P = 0.003) and for 92.1% versus 89.9% at 
visit 5 (P = 0.0287) in the LE   ointment and vehicle groups, 
respectively. At visit 6, there was a s  ignificant difference in 
the proportion of eyes with stable or improved photophobia 
(90.8% versus 84.2%, respectively, P = 0.0157) but no 
difference in the p  resence of photophobia. Visit 6 tearing 
rate was significantly lower in the LE   ointment group when 
controlling for center (P = 0.1216/0.0482; Pearson/Cochran-
Mantel-Haenszel).
safety outcomes
Ocular adverse events were consistent with ocular signs 
after cataract surgery. Table 3 presents a listing of ocular 
adverse events that occurred in $3% of study eyes prior to 
rescue medication. There was a lower incidence of ocular 
adverse events in the LE ointment treatment group versus the 
vehicle treatment group, and the percentage of patients who 
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Figure 3 Proportion of patients with complete resolution of anterior chamber inflammation A), complete resolution of anterior chamber cells B), complete resolution of 
anterior chamber flare C), and no (grade 0) pain D) at each study visit. 
Notes: Visit 4 = day 3 (±1 day); visit 5 = day 8 (±1 day); visit 6 = day 15 (±1 day); visit 7 = day 18 (±1 day). *P , 0.0001; †P = 0.0008.
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had one or more ocular adverse events was significantly less 
in the LE ointment group (47.2%) than in the vehicle group 
(78.0%, P , 0.0001). The most prevalent ocular adverse 
events with LE ointment were ACI, photophobia, corneal 
edema, conjunctival hyperemia, eye pain, and iritis. Ocular 
adverse events that occurred at statistically different rates 
between treatment groups included ACI, conjunctival hyper-
emia, eye pain, iritis, ciliary hyperemia, increased lacrimation, 
and eye pruritus. In each case, these ocular adverse events 
occurred significantly less frequently in eyes randomized 
to LE ointment (P # 0.0336). Most ocular adverse events 
were considered unrelated or unlikely to be related to study 
treatment (72.5% [227/313] and 63.3% [368/581] for the LE 
ointment and vehicle treatment groups, respectively). Most 
ocular adverse events considered definitely related to study 
treatment were of mild or moderate severity (82.6% [19/23] 
across treatment groups). Four of the adverse events were 
definitely related to treatment and included ACI (two vehicle), 
eye pain (LE ointment), and eye irritation (LE ointment).
The protocol required the recording of an adverse event 
of ACI prior to initiation of rescue therapy. To   differentiate 
between adverse events related to increased ACI and 
those cases where inflammation was stable or improved, 
a supplemental analysis was performed in which any adverse 
event associated with rescue medication without increased 
inflammation relative to visit 3 (baseline) was removed 
from the listing. Patients with stable ACI of maximum 
severity (Grade 8) at the rescue visit, however, remained in 
the a  nalysis. Results from this additional analysis showed 
that ACI adverse event rates in the study eye prior to rescue 
medication use decreased from the original rates of 27.2% 
(110 patients) versus 50.0% (200 patients) for LE ointment 
versus vehicle treatment groups to 12.8% (52 patients) and 
27.5% (110 patients), respectively (P , 0.0001 for both).
Nonocular adverse events were less commonly reported. 
The percentage of patients who had one or more nonocular 
adverse events did not differ between the LE ointment treat-
ment group and the vehicle treatment group (5.2% [21/405] 
and 4.5% [18/400], respectively, P = 0.743). The only non-
ocular adverse event reported at a rate of at least 1% was 
headache (1.5% [6/405] and 1.3% [5/400], respectively, 
P . 0.9999).
There were no deaths during the study period. Three patients 
in the vehicle treatment group withdrew from the study due 
to a serious adverse event. All three serious adverse events 
were considered by the investigator to be unrelated to the 
study drug. One patient developed endophthalmitis, which 
resolved through use of antibiotics, and was considered by the 
investigator to be related to the study procedure (ie, cataract 
surgery). The other two were discontinued due to nonocular 
serious adverse events. Other serious adverse events were 
all nonocular, with the exception of one report of cystoid 
macular edema in the LE ointment group. Three additional 
ocular serious adverse events were reported at study exit, 
and included mild cystoid macular edema present in three 
vehicle-treated patients.
Mean baseline (postoperative day 1) IOP for study eyes 
was similar between treatment groups. At subsequent visits, 
mean IOP was consistently lower than baseline for both 
treatment groups (Figure 4). Over the course of the study, 
Table 3 Ocular adverse events occurring in $3% study eyes in 
any treatment group prior to rescue medication
LE ointment 
(n = 405)
Vehicle 
(n = 400)
P valuea
Total number of Aes 313 581
number of patients  
  with at least one Ae
191 (47.2%) 312 (78.0%) ,0.0001
    Anterior chamber  
inflammation
110 (27.2%) 200 (50.0%) ,0.0001
  Photophobia 22 (5.4%) 31 (7.8%) 0.2025
  Corneal edema 18 (4.4%) 23 (5.8%) 0.4264
  Conjunctival hyperemia 16 (4.0%) 30 (7.5%) 0.0336
  eye pain 15 (3.7%) 43 (10.8%) 0.0001
  iritis 15 (3.7%) 31 (7.8%) 0.0149
  Ciliary hyperemia 10 (2.5%) 23 (5.8%) 0.0208
  Anterior chamber cell 10 (2.5%) 16 (4.0%) 0.2375
  Lacrimation increased 8 (2.0%) 19 (4.8%) 0.0318
  eye pruritus 6 (1.5%) 19 (4.8%) 0.0080
  Anterior chamber flare 6 (1.5%) 14 (3.5%) 0.0731
Notes: Data are the number (%) of eyes. aP values were calculated using the Fisher’s 
exact test. A patient was counted at most once for a given preferred term (except 
for total number of Aes).
Abbreviations: Aes, adverse events; Le, loteprednol etabonate.
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four patients (three LE ointment and one vehicle) had IOP 
elevations $10 mmHg from baseline prior to rescue medica-
tion, with a maximum IOP of 32 mmHg for an LE ointment-
treated subject at visit 5. The difference between treatment 
groups in the percentage of study eyes with an increase in 
IOP $10 mmHg from baseline was not significant at any 
post-baseline visit.
The distribution of slit lamp signs reported at baseline 
(postoperative day 1) was similar between treatment groups. 
At visits 4–7, the proportion of patients with an increase in 
severity from baseline for each ocular sign were consistently 
either similar between treatments or significantly different 
between treatments in favor of LE ointment. There were no 
instances where there was a significant difference in favor 
of the vehicle (data not shown).
Dilated funduscopy and visual acuity results were com-
parable across treatment groups and visits with few excep-
tions. No fundus pathology was noted for the majority of 
eyes (.80%) at baseline and there was only one treatment-
emergent finding at visit 6 of a mild retina hemorrhage in an 
eye treated with LE ointment that was normal at screening. 
At visits 5 and 6, significantly fewer eyes treated with LE 
ointment had a $2 line drop in visual acuity from baseline 
compared with vehicle (1.9% [7/367] versus 7.2% [19/264], 
P = 0.0010 at visit 5) and (0.6% [2/348] versus 2.8% [5/180], 
P = 0.0359 at visit 6).
Discussion
LE ointment 0.5% administered four times daily for 14 days 
postoperatively was shown to be superior to vehicle in 
the treatment of inflammation and pain following cataract 
surgery in this integrated analysis of two randomized, mul-
ticenter, double-masked, parallel-group, vehicle-controlled 
studies. A significantly greater proportion of patients ran-
domized to LE ointment had complete resolution of ACI 
and no (Grade 0) pain at postoperative day 8 compared with 
patients randomized to vehicle (P , 0.0001 for both). Also, 
fewer patients in the LE ointment group than in the vehicle 
group required rescue medication during the course of the 
study. Secondary analyses were consistent with the primary 
analysis. These included analyses at individual visits for 
complete resolution of ACI, for cells and flare considered 
separately, for the change from baseline ACI severity, and 
for no pain. Resolution of ACI was significantly improved 
(P , 0.001) at visit 4 (postoperative day 3), while cells 
were not significantly different until visit 5, suggesting that 
a dosing period of more than three days may be required for 
postoperative resolution of cells.
Treatment with LE ointment was well tolerated and safe. 
Symptoms of ocular pain, photophobia, and tearing between 
the treatment groups and their change from baseline signifi-
cantly favored LE ointment at most visits, while symptoms 
of ocular discharge, dryness, and itching were consistently 
  similar across the treatment groups, with few exceptions. 
  Ocular adverse events were consistent with ocular signs after 
cataract surgery and occurred less frequently,   overall, in the LE 
ointment group compared with the vehicle group. The most 
common ocular adverse events in patients   randomized to LE 
ointment were ACI, photophobia, corneal edema, conjunctival 
hyperemia, eye pain, and iritis. Of these, ACI, conjunctival 
hyperemia, eye pain, and iritis occurred significantly less fre-
quently in the LE ointment compared with the vehicle group 
(P , 0.05). Headache was the only nonocular adverse event, 
and was reported by more than 1% of patients.
Mean IOP for all study eyes in both treatment groups 
was consistently lower than baseline at all post-treatment 
visits. Prior to rescue medication, there were only four 
patients who had an IOP increase of $10 mmHg from 
baseline over the course of the study (three LE ointment 
and one vehicle). These findings are consistent with the low 
incidence of clinically significant IOP elevations observed in 
studies of LE 0.5% ophthalmic suspension in postoperative 
inflammation following cataract surgery,16,17 as well as other 
indications,19,21 and are attributed to the rapid de-esterification 
of LE to inactive metabolites.5,6 Dilated funduscopy results 
were comparable across treatment groups, while significantly 
fewer eyes treated with LE ointment had a $2 line drop in 
visual acuity from the day 1 postoperative visit compared 
with vehicle-treated eyes at visits 5 and 6.
The availability of an ointment formulation for LE 
allows physicians an additional choice in dosage forms 
when treating patients with ocular inflammation. Ointment 
formulations increase the ocular contact time of applied 
drugs approximately two-fold in blinking eyes and four-fold 
in the n  onblinking (patched) eyes as compared with saline 
vehicle.22 They are generally used to increase drug absorption 
for night-time therapy or for treating children because they 
do not wash out readily with tearing. Disadvantages include 
transient blurred vision and more difficult a  dministration.22 
  Fluorometholone ointment 0.1% is currently the only 
approved ophthalmic t  opical corticosteroid ointment in the 
US, and is indicated for the treatment of steroid-responsive 
inflammation of the palpebral and bulbar conjunctiva, 
c  ornea, and anterior   segment of the globe.23 There has been 
only one clinical study comparing the safety and efficacy 
of any LE ophthalmic formulation with a fluorometholone Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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ophthalmic formulation. Stewart compared the efficacy and 
safety of fluorometholone acetate 0.1% suspension with LE 
ophthalmic suspension 0.5%, both administered four times 
a day for 14 days in a small r  andomized, double-masked, 
parallel-group study (n = 30) of patients with postoperative 
inflammation following c  ataract surgery.24 No statistical 
differences were found between treatments in resolution 
of flare, anterior chamber cells, or conjunctival hyperemia, 
and there were no significant adverse events in either group. 
Concentrations of active ingredients in the formulations 
compared in the Stewart study were the same as those in their 
respective ointment formulations; however, both formulations 
contained benzalkonium chloride 0.01% as a preservative.10,25 
LE o  intment is preservative-free, while fluorometholone 
  ointment is preserved with 0.0008% p  henylmercuric acetate,23 
a preservative subject to d  egradation to mercury and which 
has been associated with time- and dose-dependent ocular 
cytotoxicity26 and periorbital contact dermatitis.27
Both Howes et al and Samudre et al studied the anti-
inflammatory activity of LE ophthalmic suspension 0.5% in 
comparison with that of other topical ophthalmic steroids, 
including fluorometholone acetate 0.1% suspension, in a 
rabbit model of acute anterior uveitis.28,29 While there was no 
difference between fluorometholone acetate and LE in reduc-
ing anterior chamber cells and iris hyperemia in the study by 
Howes et al, LE was less effective in reducing conjunctival 
injection, anterior chamber flare, and protein.28 In contrast, 
Samudre et al reported that LE 0.5% was associated with 
the most glucocorticoid receptor migration compared with 
other ophthalmic steroids, including fluorometholone, and 
was highly efficacious using several independent measures 
of steroid anti-inflammatory efficacy.29 In addition, confocal 
microscopy indicated that only LE reverted abnormal corneal 
endothelial cell shape back to normal.29 These results sug-
gest that there may be some differences in efficacy between 
LE and fluorometholone that warrant further study. Fluo-
rometholone itself is a C-20 ketone corticosteroid, and there 
have been case reports of fluorometholone-induced cataract 
formation in the literature.30,31 As indicated earlier, LE is a 
C-20 ester corticosteroid, and therefore does not form Schiff 
base intermediates with lens protein, a likely first step in 
cateracterogenesis.9 Finally, Cantrill et al reported a mean 
increase in IOP from baseline of 6.1 ± 1.4 mmHg with fluo-
rometholone acetate 0.1% suspension in steroid-responsive 
subjects (n = 6) treated four times daily for two to six weeks;32 
while Bartlett reported a mean IOP rise of 4.1 mmHg in 
steroid-responsive subjects treated with LE ophthalmic sus-
pension 0.5% (n = 14) also treated four times daily but for a 
full six weeks, a change from baseline that was not statisti-
cally significant.7 These findings suggest that there may also 
be differences in safety with these two steroids.
In conclusion, the integrated results of these studies indicate 
that LE ointment is effective and well tolerated in the treatment 
of postoperative inflammation and pain following ocular sur-
gery. The availability of an ointment formulation of the already 
well characterized LE 0.5% concentration allows physicians 
a choice of dosage forms in treating ocular inflammation fol-
lowing ocular surgery. The availability of a preservative-free 
ointment formulation of LE may provide a safety advantage 
over fluorometholone ointment, although further randomized 
comparative clinical studies are warranted.
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